Targeting a Novel ER/HOXB7 Signaling Loop in Tamoxifen-Resistant Breast Cancer

The majority of patients with breast cancer present with an estrogen receptor-positive (ER(+)) tumor, and the endocrine agent tamoxifen is a mainstay for their treatment. Unfortunately, however, resistance remains a major problem because most patients who respond eventually have a recurrence. Thus,...

Full description

Saved in:

Bibliographic Details
Published in:	Cancer discovery Vol. 5; no. 9; p. 909
Main Authors:	Heideman, Marinus R, Frei, Anna, Hynes, Nancy E
Format:	Journal Article
Language:	English
Published:	United States 01.09.2015
Subjects:	Animals Antineoplastic Agents, Hormonal - pharmacology Drug Resistance, Neoplasm - genetics Estrogen Receptor alpha - metabolism Female Gene Expression Regulation, Neoplastic Homeodomain Proteins - metabolism Humans Receptor, ErbB-2 - metabolism
ISSN:	2159-8290, 2159-8290
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The majority of patients with breast cancer present with an estrogen receptor-positive (ER(+)) tumor, and the endocrine agent tamoxifen is a mainstay for their treatment. Unfortunately, however, resistance remains a major problem because most patients who respond eventually have a recurrence. Thus, an enduring challenge in the breast cancer field is to identify mechanisms underlying tamoxifen resistance. Jin and colleagues describe a novel ER/HOXB7 signaling loop in tamoxifen-resistant breast cancer models. Importantly, they reveal that targeting this signaling loop has great promise as an approach to treat patients with tamoxifen-resistant breast cancer.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Commentary-3 content type line 23
ISSN:	2159-8290 2159-8290
DOI:	10.1158/2159-8290.CD-15-0871